Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Insights, Forecast to 2025
A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
In the last several years, global market of Commercializing Biomarkers in Therapeutic and Diagnostic Applications developed rapidly, with an average growth rate of 8.49%. In 2015, the consumables revenue growth rate was about 8.5%, the services revenue growth rate was nearly 8.6%, and the consumables revenue growth rate was the highest among the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry.
North America is the largest consumer of Commercializing Biomarkers, with the sales market share nearly 42%.
The second place is Europe, following North America with the sales market share of 31%. Japan and China is also the important market, with the total sales marker share of 18.6%.
The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market is valued at 17200 million US$ in 2018 and will reach 24900 million US$ by the end of 2025, growing at a CAGR of 4.8% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Commercializing Biomarkers in Therapeutic and Diagnostic Applications market based on company, product type, end user and key regions.
This report studies the global market size of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in these regions.
This research report categorizes the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market by top players/brands, region, type and end user. This report also studies the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Market size by Product
Consumables
Services
Software
Market size by End User
Oncology
Cardiology
Neurology
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Commercializing Biomarkers in Therapeutic and Diagnostic Applications market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Commercializing Biomarkers in Therapeutic and Diagnostic Applications are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Commercializing Biomarkers in Therapeutic and Diagnostic Applications market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
In the last several years, global market of Commercializing Biomarkers in Therapeutic and Diagnostic Applications developed rapidly, with an average growth rate of 8.49%. In 2015, the consumables revenue growth rate was about 8.5%, the services revenue growth rate was nearly 8.6%, and the consumables revenue growth rate was the highest among the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry.
North America is the largest consumer of Commercializing Biomarkers, with the sales market share nearly 42%.
The second place is Europe, following North America with the sales market share of 31%. Japan and China is also the important market, with the total sales marker share of 18.6%.
The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market is valued at 17200 million US$ in 2018 and will reach 24900 million US$ by the end of 2025, growing at a CAGR of 4.8% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Commercializing Biomarkers in Therapeutic and Diagnostic Applications market based on company, product type, end user and key regions.
This report studies the global market size of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in these regions.
This research report categorizes the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market by top players/brands, region, type and end user. This report also studies the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Market size by Product
Consumables
Services
Software
Market size by End User
Oncology
Cardiology
Neurology
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Commercializing Biomarkers in Therapeutic and Diagnostic Applications market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Commercializing Biomarkers in Therapeutic and Diagnostic Applications are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Commercializing Biomarkers in Therapeutic and Diagnostic Applications market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
